Cancer is not one condition but many. Each patient’s disease has its own unique genomic, and other, variations that make it unique. In addition, cancer is not a stationary target but rather an evolving disease that seeks, more than anything, to survive.
Fortunately, new approaches have emerged in the past few years that are giving researchers and clinicians new tools to take on cancer. Genomic sequencing can identify cancer-driving mutations. Targeted drugs can help knock down those variations. Immunotherapies can mobilize the body’s natural defenses to eradicate tumors.
"Cancer Therapeutics seeks to build on these successes by developing new and innovative treatments. Quite often, that means creating therapies that hone in on tumor cells but leave healthy tissues alone."
That's where GNF's collaborative environment pays dividends. Multidisciplinary teams of chemists, protein scientists, biologists and engineers are developing new ways to create drugs, making them more focused on tumors and less systemically active. That could mean combining cytotoxic agents or targeted molecules with antibodies or developing drugs that can be turned on only after they reach the tumor. The ultimate goal is to hit cancer harder while simultaneously boosting patient safety.
GNF has created one the world's most sophisticated drug development engines: an enormous small molecule library; robust protein engineering expertise; platforms to create unique anti-cancer compounds. GNF's in-house engineering group provides added horsepower, designing new cameras, microfluidics platforms and many other tools to advance cancer research.
The group's top priority is creating first-in-class medicines that generate long-term responses in patients while generating fewer side effects. With deep motivation, freedom to innovate and in-house experts that can help develop new research technologies, they are poised for continued success.